Luke Pase
Chief Technology Officer Anocca AB
Seminars
Thursday 10th September 2026
Designing a Library of TCR T Cell Therapy Products that Precisely Target Mutant KRAS
9:30 am
- Selecting and validating high value KRAS targets systemized cell biology assays
- Defining potent and selective TCR assets that form the foundation of differentiated TCR T therapy products
- Scaling manufacturing and clinical trial design to enable meet the needs of highly personalized cell therapies
